Karl Kieburtz
| Title | Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Neurology in the Center for Human Experimental Therapeutics |
|---|
| Address | Center for Human Exp. Therapeutics
Box 694
265 Crittenden Blvd.
Rochester NY 14642
|
|---|
|
|
|
| Title | Director |
|---|
| Institution | University of Rochester Medical Center |
|---|
| Department | Center for Human Experimental Therapeutics |
|---|
|
|
|---|
| Title | Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Environmental Medicine |
|---|
|
|
|---|
|
|
|
|
| HONORS:
Phi Beta Kappa, Amherst College, 1980;
Frank Dow Award in Chemistry, Amherst College, 1980;
Logan Clendenning Fellowship in the History of Medicine, 1982;
George W. Merck Dean's Teaching Scholar, University of Rochester School of Medicine 1994-1997;
The Best Doctors in America, Woodward/White, Inc., 2nd edition, 1994 | |
|
|
| Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism (DATATOP) NS24778 | NINDS, NIH 11/89-4/94 | |
|
|
| Dideoxyinosine treatment of AIDS Dementia | Industry Sponsored Clinical Trial 10/90-11/91 | |
|
|
| Parkinson Study Group START Clinical Trials | Industry Sponsored 11/1/90-4/30/92 | |
|
|
| AIDS Clinical Trial Group | National Institute of Allergy and Infectious Disease, NIH | |
|
|
| Parkinson Study Group ROADS Clinical Trial | Industry Sponsored | |
|
|
| BLIND-DATE Clinical Trial | Industry Sponsored | |
|
|
| Glutamate Antagonist Tolerability in Huntington's Disease | Industry Sponsored Clinical Trial | |
|
|
| STEP-UP Clinical Trial | Industry Sponsored | |
|
|
| European Network for Striatal Transplantation in Huntington's Disease(NEST-HD):preclinical development & clinical trial method | European Economic Community | |
|
|
| Experimental Therapeutics of HIV Neurology (part of Neurologic AIDS Research Consortium Program Project, David Clifford, PI) | NINDS, NIH | |
|
|
| SEESAW Clinical Trial | Industry Sponsored | |
|
|
| Dana Foundation Consortium For The Treatment of HIV Dementia And Related Disorders | |
|
|
| A Double Blind Study of Amitriptyline and Mexilitine for Painful HIV Neuropathy | AIDS Clinical Trials Group, Protocol 242, 2/94-2/96 | |
|
|
| Clozapine for Psychosis in PD | FDA, Orphan Drug Div. | |
|
|
| Investigation of Tolerability of OPC-14117 in Huntington's Disease | Otsuka Pharmaceuticals | |
|
|
| Trial of a Glutamate Antagonist in PD and MSA | Industry Sponsored | |
|
|
| Evaluation of SPECT Imaging in The Diagnosis of PD | Industry Sponsored | |
|
|
| Comparison of Levodopa and a Dopamine Agonist in PD | Industry Sponsored | |
|
|
| PSG PRIME: Study of a Dopamine Agonist in Minority Persons | Industry Sponsored | |
|
|
| TACT Study: Treatment of ADHD in Children with Tourette's | NIH NINDS, RO1 NS33654 | |
|
|
| PSG SPIRAL Study: Interaction Study of Remacemide and Levodopa in Parkinson's Disease | Industry Sponsored | |
|
|
| Clinical Trials Unit in HIV Dementia | NINDS, NIH, P01 NS32228 | |
|
|
| Co-Enzyme Q10 and Remacemide Evaluation in Huntington's Disease | NIH, RO1 NS35284 | |
|
|
| Neurocognitive Function, HIV Load and Surrogate Markers (NEAD) | NIH, P01 NS36519-01A1 | |
|
|
| Earlier vs. Later L-dopa in Parkinson's Disease | NIH, R01 NS34796-01A1 | |
|
|
| Effects of Coenzyme Q10 in Patients With Early, Untreated Parkinson's Disease | NIH R01 NS36714 | |
|
|
| Midcareer Investigator Award in Patient-Oriented Research | NINDS, NS02122 | |
|
|
| ERSET: A Multi-center Randomized Clinical Trial for Early Treatment of Epilepsy | NIH, NS37897 | |
|
|
| Alzheimer's Disease Cooperative Study | 5U01-AG010483 | |
|
|
| PSG PATCH Study: Topical Dopamine Agonist in PD | Industry Sponsored | |
|
|
| PSG RAPID Study: Monoamine Oxidase Inhibitor in PD | Industry Sponsored | |
|
|
| Ethylester of Levodopa in PD | Industry Sponsored | |
|
|
| Early Randomized Surgical Epilepsy Trial | NIH R21 NS42372 | |
|
|
| Targeted Neuroprotection for HIV-1 Associated Neurologic Disease | NIH PO1 MH64570 | |
|
|
| Neuroprotection Studies in PD: A Coordinating Center | NIH, NINDS NS43128 | |
|
|
| Neurobiological Predictors of Huntington's Disease (PREDICT-HD) | NINDS NS40068 | |
|
|
| Prospective Huntington At-Risk Observational Study (PHAROS) | Huntington's Disease Society of America & Hereditary Disease Fdn | |
|
|
| Prospective Huntington At-Risk Observational Study (PHAROS) | NIH / NHGRI / NINDS R01HG02449 | |
|
|
| HSG Trend Study: A multicenter placebo-controlled efficacy and safety trial of an experimental membrane-stabilizing drug | ethyl-EPA in ambulatory Huntington's Disease patients | |
|
|
| HSG DOMINO Study: Double blind study of minocycline in Huntington's disease | FD-R-02588 | |
|
|
| Multi-Center Phase 1-2A Open-Label Dose-Escalation & Randomized, Double-Blind, Placebo-controlled Study of Dimebon in Subjects | w/ HD (DIMOND) Industry Sponsored | |
|
|
| PSG Prami BID Study: A randomized, double-blind, active and placebo controlled, efficacy study of pramipexole in subjects w/ PD | Industry Sponsored | |
|
|
| The University of Rochester's Clinical and Translational Science Institute | UL1 RR024160, KL2 RR024136, TL1 RR024135 | |
|
|
| Neuroprotection Studies in PD: A Coordinating Center | NIH, NINDS NS43128 | |
|
|
| Midcareer Investigator Award in Patient-Oriented Research | NINDS, NS02122 | |
|
|
| Data Coordination and Biostatistics Center for the NORDIC Network | National Eye Institute, 1U10 EYO17387-01A1 | |
|
|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate | Huntington Disease (HORIZON): Medivation | |
|
|
| A multi-center, N.A., randomized, double-blind, parallel group study comparing three doses of ACR16... (HART) | NeuroSearch Sweden AB | |
|
|
| Inosine for Parkinson's Disease: Safety and Trial Design Optimization | Michael J. Fox Foundation Rapid Response Innovation Award | |
|
|
| Coordination and Statistics for CoQ10 in HD (2CARE) | NIH NINDS RO1 NS052619 | |
|
|
| Prophylactic Phenobarbital after Resolution of Neonatal Seizures (PROPHENO) | NICHD, RO1 HD057977 | |
|
|
| Ethics of Sham Surgery Controls to Test Novel Parkinson's Disease Interventions | Michael J. Fox Foundation Rapid Response Innovation Award | |
|
|
| PSG PRECEPT study, CEP1347 in Early PD | Industry Sponsored |
Karl Kieburtz, MD, MPH, is the T1 Translation Key Function Director and the Director of the Center for Human Experimental Therapeutics (CHET) at the URMC. He is the Robert J. Joynt Professor in Neurology and Professor of Community and Preventive Medicine and Environmental Medicine. CHET conducts learning phase clinical trials in a wide spectrum of disorders in collaboration with investigators within the University of Rochester Medical Center (URMC) as well as with colleagues throughout North America, Europe, Asia and Oceania. Dr Kieburtz's primary clinical and research interests are neurodegenerative diseases affecting the basal ganglia, particularly Parkinson disease, Huntington disease, and HIV related neurologic disorders. He is the principal investigator for the NINDS sponsored trials of neuroprotective agents for PD (NET-PD) and directs the Coordination Center for an NEI-funded consortium in Neuro-opthalmology. He completed his MD and MPH degrees at the University of Rochester, as well as his Neurology residency and a fellowship in Experimental Therapeutics.
-
Kim SY, De Vries R, Holloway RG, Wilson R, Parnami S, Kim HM, Frank S, Kieburtz K. Sham surgery controls in Parkinson's disease clinical trials: Views of participants. Mov Disord. 2012 Sep 15; 27(11):1461-5.
-
Galpern WR, Corrigan-Curay J, Lang AE, Kahn J, Tagle D, Barker RA, Freeman TB, Goetz CG, Kieburtz K, Kim SY, Piantadosi S, Comstock Rick A, Federoff HJ. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol. 2012 Jul; 11(7):643-50.
-
Engel J, McDermott MP, Wiebe S, Langfitt JT, Stern JM, Dewar S, Sperling MR, Gardiner I, Erba G, Fried I, Jacobs M, Vinters HV, Mintzer S, Kieburtz K. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012 Mar 7; 307(9):922-30.
-
Kim SY, Wilson RM, Kim HM, Holloway RG, De Vries RG, Frank SA, Kieburtz K. Comparison of enrollees and decliners of Parkinson disease sham surgery trials. Mov Disord. 2012 Apr; 27(4):506-11.
-
Yerramilli-Rao P, Beal MF, Watanabe D, Kieburtz K, Blieck EA, Kitano M, Hosoe K, Funahashi I, Cudkowicz ME. Oral repeated-dose toxicity studies of coenzyme q10 in beagle dogs. Int J Toxicol. 2012 Jan; 31(1):58-69.
-
Kieburtz K, Venuto C. TRACK-HD: both promise and disappointment. Lancet Neurol. 2012 Jan; 11(1):24-5.
-
Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord. 2012 Jan; 27(1):31-41.
-
Constantinescu R, Romer M, Zetterberg H, Rosengren L, Kieburtz K. Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord. 2011 Nov; 17(9):714-5.
-
Olanow CW, Wunderle KB, Kieburtz K. Milestones in movement disorders clinical trials: advances and landmark studies. Mov Disord. 2011 May; 26(6):1003-14.
-
Goodman L, Sia C, Carnes R, Vetter L, Taubman F, Venuto CS, McGarry A, Kieburtz K, Agarwal P. Advocacy Recruiting for Huntington's Disease Clinical Trials. PLoS Curr. 2011; 3:RRN1230.
-
Pearson TA, Fogg TT, Bennett N, Kieburtz K, Kitzman H, Moxley R, Puzas E. Building capacity across the spectrum of research translation: centers of excellence within the Rochester Clinical and Translational Science Institute. Clin Transl Sci. 2010 Dec; 3(6):272-4.
-
Kieburtz K. Discovering neuroprotection in Parkinson's disease, or getting to haphazard. Mt Sinai J Med. 2010 Nov-Dec; 77(6):700-6.
-
Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-72.
-
Kieburtz K. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord. 2011 Jan; 26(1):37-44.
-
Engel J, McDermott MP, Wiebe S, Langfitt JT, Erba G, Gardiner I, Stern J, Dewar S, Sperling MR, Jacobs M, Kieburtz K. Design considerations for a multicenter randomized controlled trial of early surgery for mesial temporal lobe epilepsy. Epilepsia. 2010 Oct; 51(10):1978-86.
-
Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
-
Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD--a road map for moving forward. Mov Disord. 2010 Sep 15; 25(12):1774-9.
-
Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord. 2010 Sep 15; 25(12):1924-8.
-
Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
-
Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, Appel S, Ravina B, Kieburtz K, Shoulson I, Kaufmann P, Khan J, Simpson E, Shefner J, Levin B, Cwik V, Schoenfeld D, Aggarwal S, McDermott MP, Miller RG. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010 May 3; 11(3):259-65.
-
Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol. 2010 Feb; 67(2):154-60.
-
Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord. 2010 Jan 30; 25(2):224-8.
-
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1460-8.
-
Kieburtz K. ADAGIO misses a beat? Lancet Neurol. 2009 Dec; 8(12):1081-2.
-
Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
-
Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, Elm J, Ravina B, Bergmann KJ, Kieburtz K. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
-
Kim SY, Schrock L, Wilson RM, Frank SA, Holloway RG, Kieburtz K, de Vries RG. An approach to evaluating the therapeutic misconception. IRB. 2009 Sep-Oct; 31(5):7-14.
-
Guttuso T, McDermott MP, Ng P, Kieburtz K. Effect of L-methionine on hot flashes in postmenopausal women: a randomized controlled trial. Menopause. 2009 Sep-Oct; 16(5):1004-8.
-
Kupersmith MJ, Miller N, Balcer L, Gordon L, Wall M, Keltner J, Friedman D, Feldon S, McDermott M, Kieburtz K. The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC). J Neuroophthalmol. 2009 Sep; 29(3):259-61.
-
Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol. 2009 Aug; 66(2):184-90.
-
Ravina B, Swearingen C, Elm J, Kamp C, Kieburtz K, Kim SY. Long term understanding of study information in research participants with Parkinson's disease. Parkinsonism Relat Disord. 2010 Jan; 16(1):60-3.
-
Dworkin RH, Barbano RL, Tyring SK, Betts RF, McDermott MP, Pennella-Vaughan J, Bennett GJ, Berber E, Gnann JW, Irvine C, Kamp C, Kieburtz K, Max MB, Schmader KE. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009 Apr; 142(3):209-17.
-
Constantinescu R, Romer M, Oakes D, Rosengren L, Kieburtz K. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. Parkinsonism Relat Disord. 2009 Mar; 15(3):245-8.
-
Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol. 2008 Dec; 64 Suppl 2:S101-10.
-
Kieburtz K. Therapeutic strategies to prevent motor complications in Parkinson's disease. J Neurol. 2008 Aug; 255 Suppl 4:42-5.
-
Kim SY, Holloway RG, Frank S, Wilson R, Kieburtz K. Trust in early phase research: therapeutic optimism and protective pessimism. Med Health Care Philos. 2008 Dec; 11(4):393-401.
-
Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord. 2008 Jul 15; 23(9):1223-7.
-
Guttuso T, McDermott MP, Su H, Kieburtz K. Effects of L-isoleucine and L-valine on hot flushes and serum homocysteine: a randomized controlled trial. Obstet Gynecol. 2008 Jul; 112(1):109-15.
-
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
-
Frank SA, Wilson R, Holloway RG, Zimmerman C, Peterson DR, Kieburtz K, Kim SY. Ethics of sham surgery: perspective of patients. Mov Disord. 2008 Jan; 23(1):63-8.
-
Constantinescu R, McDermott MP, Dicenzo R, de Blieck EA, Hyson HC, Beal MF, Bednarczyk EM, Bogdanov M, Metakis LJ, Browne SE, Lorenzo BJ, Ravina B, Kieburtz K. A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone). J Clin Pharmacol. 2007 Dec; 47(12):1580-6.
-
Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord. 2007 Jul 15; 22(9):1317-9.
-
Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB, Ross CA, Nance M, Kayson E, Julian-Baros E, Hayden MR, Kieburtz K, Guttman M, Oakes D, Shoulson I, Beglinger L, Duff K, Penziner E, Paulsen JS. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain. 2007 Jul; 130(Pt 7):1732-44.
-
Kieburtz K, Ravina B. Why hasn't neuroprotection worked in Parkinson's disease? Nat Clin Pract Neurol. 2007 May; 3(5):240-1.
-
Constantinescu R, Romer M, Kieburtz K. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord. 2007 Apr 15; 22(5):720-2.
-
Kieburtz K, Olanow CW. Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy. Mt Sinai J Med. 2007 Apr; 74(1):7-14.
-
Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, Ross CA, Beglinger L, Hayden MR, Kieburtz K, Kayson E, Julian-Baros E, Duff K, Guttman M, Nance M, Oakes D, Shoulson I, Penziner E, Paulsen JS. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia. 2007 Apr 9; 45(8):1767-76.
-
Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, Conant K, Selnes OA, Stern Y, McClernon DR, Palumbo D, Kieburtz K, Riggs G, Cohen B, Marder K, Epstein LG. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol. 2007 Jan; 64(1):97-102.
-
Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, Hubble J. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2006 Dec; 5(12):1013-20.
-
deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord. 2006 Oct; 21(10):1716-21.
-
Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006 Jun; 63(6):883-90.
-
Kieburtz K. Issues in neuroprotection clinical trials in Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S50-7.
-
Kim SY, Kieburtz K. Appointing a proxy for research consent after one develops dementia: the need for further study. Neurology. 2006 May 9; 66(9):1298-9.
-
Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006 May; 21(5):616-23.
-
Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I. Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn. 2006 Jun; 33(3):281-311.
-
Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
-
Kim SY, Frank S, Holloway R, Zimmerman C, Wilson R, Kieburtz K. Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers. Arch Neurol. 2005 Sep; 62(9):1357-60.
-
Frank S, Kieburtz K, Holloway R, Kim SY. What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology. 2005 Oct 11; 65(7):1101-3.
-
Marras C, Lang AE, Oakes D, McDermott MP, Kieburtz K, Shoulson I, Tanner CM, Fahn S. High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med. 2005 Jul 19; 143(2):152-3; author reply 156-8.
-
Kieburtz K, Kurlan R. Welding and Parkinson disease: is there a bond? Neurology. 2005 Jun 28; 64(12):2001-3.
-
Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord. 2005 Mar; 20(3):293-7.
-
Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
-
Guimaraes P, Kieburtz K, Goetz CG, Elm JJ, Palesch YY, Huang P, Ravina B, Tanner CM, Tilley BC. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
-
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9; 351(24):2498-508.
-
McArthur JC, McDermott MP, McClernon D, St Hillaire C, Conant K, Marder K, Schifitto G, Selnes OA, Sacktor N, Stern Y, Albert SM, Kieburtz K, deMarcaida JA, Cohen B, Epstein LG. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol. 2004 Nov; 61(11):1687-96.
-
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53.
-
Shults CW, Haas R, Oakes D, Kieburtz K, Plumb S, Shoulson I, Beal MF, Juncos J, Nutt J. Measuring the effects of therapy in Parkinson disease. JAMA. 2004 May 26; 291(20):2430-1; author reply 2431.
-
Guttuso T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003 Feb; 101(2):337-45.
-
Kieburtz K. Designing neuroprotection trials in Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S100-7; discussion S107-9.
-
Kieburtz K, McDermott M. Needed in MS: evidence, not EVIDENCE. Neurology. 2002 Nov 26; 59(10):1482-3.
-
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct; 59(10):1541-50.
-
Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord. 2002 Jul; 17(4):758-63.
-
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May; 51(5):604-12.
-
Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002 Apr; 8(2):136-42.
-
Schifitto G, Barbano RL, Kieburtz KD, Cohn SE, Zwillich SH. HIV related vasculitic mononeuropathy multiplex: a role for IVIg? J Neurol Neurosurg Psychiatry. 1997 Aug; 63(2):255-6.
-
Ketonen L, Kieburtz KD, Tuite MJ, Eskin T, Simon J. CNS lymphoma in an AIDS patient involving the posterior fornix case report. J NeuroAIDS. 1997; 1(3):43-9.
-
Kieburtz KD, Price RW, Sidtis JJ, Hall C, Grundman M, McLaren C. Pilot Study of Didanosine in Patients with HIV Dementia. J NeuroAIDS. 1996; 1(4):1-5.
-
Holloway RG, Kieburtz KD. Headache and the human immunodeficiency virus type 1 infection. Headache. 1995 May; 35(5):245-55.
-
Kieburtz KD, Eskin TA, Ketonen L, Tuite MJ. Opportunistic cerebral vasculopathy and stroke in patients with the acquired immunodeficiency syndrome. Arch Neurol. 1993 Apr; 50(4):430-2.
-
Kieburtz KD, Seidlin M, Lambert JS, Dolin R, Reichman R, Valentine F. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J Acquir Immune Defic Syndr. 1992; 5(1):60-4.
-
Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch Neurol. 1991 Dec; 48(12):1281-4.
-
Kieburtz KD, Giang DW, Schiffer RB, Vakil N. Abnormal vitamin B12 metabolism in human immunodeficiency virus infection. Association with neurological dysfunction. Arch Neurol. 1991 Mar; 48(3):312-4.
-
Kieburtz KD, Ketonen L, Zettelmaier AE, Kido D, Caine ED, Simon JH. Magnetic resonance imaging findings in HIV cognitive impairment. Arch Neurol. 1990 Jun; 47(6):643-5.
-
Johnson RE, Azevedo DJ, Kieburtz KD. Variation in individual physicians' prescribing. J Ambul Care Manage. 1986 Feb; 9(1):25-37.
-
Kieburtz KD, Johnson RE. Prescribing rate of internists in an HMO and the influence of information sources. GHAA J. 1986; 7(1):60-71.
|
Kieburtz's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
